Document Detail

Continuous infusion in haemophilia: current practice in Europe.
MedLine Citation:
PMID:  22530687     Owner:  NLM     Status:  Publisher    
Summary. Continuous infusion (CI) of factor VIII (FVIII) is an effective method for replacement therapy in haemophilia. Recently, concerns have been raised regarding association of CI with the development of inhibitors. The aim of this study was to gain information on the current practices in Europe regarding CI and the true inhibitor incidence after this mode of therapy. In a cross sectional study performed in 22 Comprehensive Care Centres (CCCs), we evaluated CI techniques, treatment protocols, efficacy, safety and complications of CI including inhibitors. Thirteen (59%) CCCs reported a total of 1079 CI treatments, given peri-operatively or for major bleeds, in 742 patients. Most centres used 'adjusted dose' CI aimed at median target FVIII level of 0.8 IU mL(-1) . CI was haemostatically very effective with a low incidence of complications: median incidence of postoperative bleeding was 1.8%, six centres observed phlebitis in 2-11% of CI treatments. Only nine (1.2%) patients developed inhibitors (0.45% of 659 severe and 7.2% of 83 mild haemophilia patients). Additional analysis of inhibitor patients revealed several confounding factors (low number of prior FVIII exposure days, high steady-state factor levels during CI, high-risk genotype). In this unprecedentedly large cohort, CI treatment appears to be an effective and safe treatment that does not increase the risk of inhibitor development in patients with severe haemophilia. Thus, previous small case series reports suggesting that CI may increase inhibitorsb cannot be confirmed. Inhibitor risk in mild haemophilia could not be evaluated as the influence of other, potentially confounding, risk factors could not be excluded.
A Batorova; P Holme; A Gringeri; M Richards; C Hermans; C Altisent; M Lopez-Fernández; K Fijnvandraat;
Related Documents :
12394287 - Carbohydrate-deficient transferrin levels reflect heavy drinking in alcohol-dependent w...
14628177 - Gender-specific differences in alcoholism: implications for treatment.
16585447 - Early weaning and hospitalization with alcohol-related diagnoses in adult life.
1318267 - Alcohol consumption as a risk factor for hepatocellular carcinoma in urban southern afr...
2802927 - Maternal influenza in the etiology of schizophrenia.
25282477 - Relationships among psychosocial factors, biomarkers, preeclampsia, and preterm birth i...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-25
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  -     ISSN:  1365-2516     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Department of Haematology and Transfusion Medicine, National Haemophilia Centre, University Hospital, Bratislava, Slovakia Haematology Medical Department, Rikshospitalet University Hospital, Oslo, Norway Centro Emofilia Angelo Bianchi Bonomi, Milan, Italy Paediatric Haematology Department, Leeds General Infirmary, Leeds, UK Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium Unitat d'Hemofilia, Hospital Universitari Vall d'Hebron, Barcelona, Spain Thrombosis and Haemostasis Unit, Servicio de Hematología y Hemoterapia, Complexo Hospitalario Universitario de A Coruña, Spain Department of Pediatric Hematology, Academic Medical Center, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Commentary.
Next Document:  Prevalence of Food Allergy in Taiwan: A Questionnaire-based Survey.